[Skip to Navigation]
August 6, 2020

Acute Macular Neuroretinopathy Associated With an Oral FLT3 Inhibitor

Author Affiliations
  • 1Department of Ophthalmology, University of California, San Francisco, San Francisco
  • 2Retina Service, University of California, San Francisco, San Francisco
JAMA Ophthalmol. 2020;138(10):1104-1106. doi:10.1001/jamaophthalmol.2020.2815

Gilteritinib is an oral FLT3 inhibitor that was approved by the US Food and Drug Administration in November 2018 for the treatment of acute myeloid leukemia (AML).1 It has been shown to improve survival and remission rates compared with salvage chemotherapy.1

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words